Cargando…

Clinical and pathological features of myeloid leukemia cutis

BACKGROUND: Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia. OBJECTIVE: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis. METHODS: This was a retrospective study of clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Wang, Yanan, Lian, Christine Guo, Hu, Nina, Jin, Hongzhong, Liu, Yuehua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916393/
https://www.ncbi.nlm.nih.gov/pubmed/29723350
http://dx.doi.org/10.1590/abd1806-4841.20186327
_version_ 1783317004867862528
author Li, Li
Wang, Yanan
Lian, Christine Guo
Hu, Nina
Jin, Hongzhong
Liu, Yuehua
author_facet Li, Li
Wang, Yanan
Lian, Christine Guo
Hu, Nina
Jin, Hongzhong
Liu, Yuehua
author_sort Li, Li
collection PubMed
description BACKGROUND: Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia. OBJECTIVE: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis. METHODS: This was a retrospective study of clinical and pathological features of 10 patients with myeloid leukemia cutis. RESULTS: One patient developed skin lesions before the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously. Of these patients, five presented with generalized papules or nodules, and five with localized masses. The biopsy of skin lesions showed a large number of tumor cells within the dermis and subcutaneous fat layer. Immunohistochemical analysis showed strong reactivity to myeloperoxidase (MPO), CD15, CD43 and CD45 (LCA) in most cases. NPM1 (nucleophosmin I) and FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) mutations were identified in one case. Five patients with acute myelogenous leukemia and one patient with chronic myelomonocytic leukemia died within two months to one year after the onset of skin lesions. STUDY LIMITATIONS: This was a retrospective and small sample study. CONCLUSIONS: In patients with myelogenous leukemia, skin infiltration usually occurs after, but occasionally before, the appearance of hemogram and myelogram abnormalities, and the presence of skin infiltration is often associated with a poor prognosis and short survival time. myeloid leukemia cutis often presents as generalized or localized nodules or masses with characteristic pathological and histochemical findings.
format Online
Article
Text
id pubmed-5916393
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Sociedade Brasileira de Dermatologia
record_format MEDLINE/PubMed
spelling pubmed-59163932018-04-30 Clinical and pathological features of myeloid leukemia cutis Li, Li Wang, Yanan Lian, Christine Guo Hu, Nina Jin, Hongzhong Liu, Yuehua An Bras Dermatol Investigation BACKGROUND: Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia. OBJECTIVE: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis. METHODS: This was a retrospective study of clinical and pathological features of 10 patients with myeloid leukemia cutis. RESULTS: One patient developed skin lesions before the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously. Of these patients, five presented with generalized papules or nodules, and five with localized masses. The biopsy of skin lesions showed a large number of tumor cells within the dermis and subcutaneous fat layer. Immunohistochemical analysis showed strong reactivity to myeloperoxidase (MPO), CD15, CD43 and CD45 (LCA) in most cases. NPM1 (nucleophosmin I) and FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) mutations were identified in one case. Five patients with acute myelogenous leukemia and one patient with chronic myelomonocytic leukemia died within two months to one year after the onset of skin lesions. STUDY LIMITATIONS: This was a retrospective and small sample study. CONCLUSIONS: In patients with myelogenous leukemia, skin infiltration usually occurs after, but occasionally before, the appearance of hemogram and myelogram abnormalities, and the presence of skin infiltration is often associated with a poor prognosis and short survival time. myeloid leukemia cutis often presents as generalized or localized nodules or masses with characteristic pathological and histochemical findings. Sociedade Brasileira de Dermatologia 2018 /pmc/articles/PMC5916393/ /pubmed/29723350 http://dx.doi.org/10.1590/abd1806-4841.20186327 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivative License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium provided the original work is properly cited and the work is not changed in any way.
spellingShingle Investigation
Li, Li
Wang, Yanan
Lian, Christine Guo
Hu, Nina
Jin, Hongzhong
Liu, Yuehua
Clinical and pathological features of myeloid leukemia cutis
title Clinical and pathological features of myeloid leukemia cutis
title_full Clinical and pathological features of myeloid leukemia cutis
title_fullStr Clinical and pathological features of myeloid leukemia cutis
title_full_unstemmed Clinical and pathological features of myeloid leukemia cutis
title_short Clinical and pathological features of myeloid leukemia cutis
title_sort clinical and pathological features of myeloid leukemia cutis
topic Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916393/
https://www.ncbi.nlm.nih.gov/pubmed/29723350
http://dx.doi.org/10.1590/abd1806-4841.20186327
work_keys_str_mv AT lili clinicalandpathologicalfeaturesofmyeloidleukemiacutis
AT wangyanan clinicalandpathologicalfeaturesofmyeloidleukemiacutis
AT lianchristineguo clinicalandpathologicalfeaturesofmyeloidleukemiacutis
AT hunina clinicalandpathologicalfeaturesofmyeloidleukemiacutis
AT jinhongzhong clinicalandpathologicalfeaturesofmyeloidleukemiacutis
AT liuyuehua clinicalandpathologicalfeaturesofmyeloidleukemiacutis